Clinical Trials Logo

Clinical Trial Summary

Subjects were tested for hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count during routine prenatal examination at 24-26 weeks of gestation, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. Those who met the criteria were included in the study group, signed the informed consent form and randomized into groups, and were given different drug administration schemes (150mg orally every day, 300mg orally every day, 150mg orally every other day, 300mg orally every other day, intravenous). At the same time, each subject was given anemia diet education, and all subjects were given folic acid 400ug/d and vitamin C 0.5g/d orally during the treatment period. If the subjects were in the oral iron group, the same time of oral iron was determined as 20 o'clock ± 1 hour in the evening, and the oral iron was not taken with other drugs; If the subject is in the intravenous medication group, the medication is scheduled to be administered at a uniform time of 8 o'clock ± 1 hour in the morning. The above subjects were followed up. Hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count were performed at 30-32 and 37 weeks of pregnancy and delivery, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. The adverse reactions were investigated with a questionnaire at the last prenatal examination before delivery. After full term delivery, the patient fills in the delivery information and enters it into the database. Finally, the data statistician and the above personnel used the blind method for statistical analysis and reached a conclusion.


Clinical Trial Description

Subjects were tested for hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count during routine prenatal examination at 24-26 weeks of gestation, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. Those who met the criteria were included in the study group, signed the informed consent form and randomized into groups, and were given different drug administration schemes (150mg orally every day, 300mg orally every day, 150mg orally every other day, 300mg orally every other day, intravenous). At the same time, each subject was given anemia diet education, and all subjects were given folic acid 400ug/d and vitamin C 0.5g/d orally during the treatment period. If the subjects were in the oral iron group, the same time of oral iron was determined as 20 o'clock ± 1 hour in the evening, and the oral iron was not taken with other drugs; If the subject is in the intravenous medication group, the medication is scheduled to be administered at a uniform time of 8 o'clock ± 1 hour in the morning. The above subjects were followed up. Hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count were performed at 30-32 and 37 weeks of pregnancy and delivery, and blood samples were taken for serum hepcidin detection in the laboratory and the values were recorded. The adverse reactions were investigated with a questionnaire at the last prenatal examination before delivery. After full term delivery, the patient fills in the delivery information and enters it into the database. Finally, the data statistician and the above personnel used the blind method for statistical analysis and reached a conclusion. 1.1 Oral iron:NIFEREX®(Each granule contains 0.15g of polysaccharide iron complex ,Kremers Urban Pharmaceuticals Inc. ) 1.2 Daily iron supplement scheme (QD):Oral polysaccharide iron complex capsule 150mg/300mg daily. 1.3 Alternative iron supplement scheme(QOD):)Oral polysaccharide iron complex capsule 150mg/300mg every other day 2.1Intravenous iron supplement:Iron Isomaltoside Injection(5ml: 500mg,Wasserburger Arzneimittelwerk GmbH),Intravenous iron supplement ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05804071
Study type Interventional
Source Qianfoshan Hospital
Contact Zhang Zhiwei, PH.D
Phone 13953109309
Email zzw_sun@163.com
Status Recruiting
Phase Phase 4
Start date March 28, 2023
Completion date January 2025

See also
  Status Clinical Trial Phase
Completed NCT03456258 - Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy N/A
Not yet recruiting NCT04074707 - Defining a Dosing Regimen With Maximal Absorption for Oral Iron Supplementation During Pregnancy N/A
Completed NCT03481790 - Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy Phase 2
Terminated NCT04594070 - Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy Phase 4
Completed NCT03706638 - Daily vs Intermittent Iron Therapy in Pregnancy N/A
Recruiting NCT06366698 - Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia Phase 3
Not yet recruiting NCT03484845 - Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy Phase 1/Phase 2
Recruiting NCT03961074 - Iron Deficiency Anemia Among Chinese Pregnant Women: a Multi-center Prospective Cohort Study
Recruiting NCT04008147 - Hepcidin and Glucose Metabolism N/A
Completed NCT03188445 - Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy. Phase 4
Completed NCT05157828 - Iron Deficiency Anaemia in Pregnant Patients Presenting for Antenatal Care
Active, not recruiting NCT05545527 - Neuroimaging Ancillary Study
Completed NCT05725278 - Impact Evaluation of Triggerise's Tiko Platform N/A
Completed NCT03378791 - Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women Phase 3
Completed NCT02005588 - Treatment of Iron Deficiency Anemia With Pregnancy Phase 0
Completed NCT03657433 - Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy Phase 3
Completed NCT04976179 - Iron Infusion Into a Vein Compared to Iron Tablet Taken by Mouth for Treating Iron Deficiency Anemia in Pregnancy (IVON) Phase 3
Completed NCT03438227 - Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial Phase 4
Available NCT05151679 - Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy